Track: CME Session
Track: Hybrid Session
David McDermott, MD
Beth Israel Deaconess Medical Center
Disclosure(s): Contract Research: Alkermes, Inc (Ongoing); BMS (Ongoing); Checkmate Pharmaceuticals (Ongoing); CRISPR Therapeutics (Ongoing); Exelixis (Ongoing); Merck (Ongoing); Pfizer (Ongoing); Roche/Genentech (Ongoing); X4 Pharma (Ongoing)
Non-CE Consulting: Alkermes, Inc (Ongoing); Aveo (Ongoing); BMS (Ongoing); Calithera (Ongoing); Eisai (Ongoing); Eli Lilly (Ongoing); EMD Serono (Ongoing); Iovance (Ongoing); Johnson & Johnson (Ongoing); Merck (Ongoing); Pfizer (Ongoing); Synthekind, Inc (Ongoing); werewolf therapeutics (Ongoing)
Daniel Shapiro, MD
University of Wisconsin-Madison
Disclosure(s): No financial relationships to disclose
Bradley Leibovich, MD
Mayo Clinic, Minnesota, United States
Disclosure(s): No financial relationships to disclose
Brian Rini, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN, United States
Disclosure(s): No financial relationships to disclose
Speaker: Bradley C. Leibovich, MD – Mayo Clinic
Award Recipient : David McDermott, MD – Beth Israel Deaconess Medical Center
Speaker: Bradley C. Leibovich, MD – Mayo Clinic
Award Recipient: Daniel Shapiro, MD – University of Wisconsin-Madison
Speaker: Brian Rini, MD – Vanderbilt-Ingram Cancer Center